Tetanus Toxoid Vaccine Market

Tetanus Toxoid Vaccine Market Size

Tetanus Toxoid Vaccine Market size was valued at USD 5 billion in 2023 and is estimated to grow at over 5.8% CAGR from 2024 to 2032. Tetanus toxoid vaccine, also known simply as tetanus vaccine, is a type of vaccine used to prevent tetanus, a serious bacterial infection caused by the bacterium Clostridium tetani. The tetanus toxoid vaccine works by stimulating the immune system to produce antibodies against the tetanus toxin. These antibodies help to neutralize the toxin and prevent the development of tetanus infection if exposed to the bacterium in the future.

The escalating incidence of tetanus and diphtheria in several countries is significantly impacting the market on multiple fronts. With the rise in tetanus and diphtheria cases, there's a heightened demand for vaccines to prevent these diseases. This surge in demand directly affects the tetanus toxoid vaccine market, stimulating vaccine manufacturers to ramp up production to meet the growing needs of affected regions. According to a World Health Organization (WHO) in 2022, approximately 84% of children globally received the recommended three doses of diphtheria-tetanus-pertussis (DTP) vaccine.

Tetanus Toxoid Vaccine Market Trends

Product launches and collaborations play significant roles in driving innovation and expanding access to tetanus toxoid vaccines, thereby contributing to the growth of the tetanus toxoid vaccine industry.

• Pharmaceutical companies frequently launch new and improved versions of tetanus toxoid vaccines to address evolving medical needs and technological advancements. These product launches introduce innovative formulations, delivery systems, and adjuvant technologies that enhance vaccine efficacy, safety, and ease of administration.
  
• For instance, in June 2021, Merck & Co. Inc. and Sanofi collaborated to launch VAXELIS (diphtheria and tetanus toxoids vaccine) in the U.S. VAXELIS is a type of combination vaccine to help in prevent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and other invasive diseases.
  

Tetanus Toxoid Vaccine Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on vaccine type, the market is segmented into tetanus toxoid (TT), diphtheria and tetanus (DT), tetanus and diphtheria (Td), diphtheria, tetanus, and pertussis (DTaP), tetanus, diphtheria, and pertussis (Tdap), diphtheria, tetanus, pertussis, Hib and hepatitis B (DTP-Hib-HepB), pentavalent (DTaP-IPV/Hib), hexavalent (DTaP-IPV/Hib-HepB), and other vaccine types. The tetanus, diphtheria, and pertussis (Tdap) segment is poised to expand at a CAGR of 6.3% between 2024 and 2032.

• Tetanus vaccines come in various formulations, and their composition may differ based on the specific vaccine, its intended use, and the target population.
  
• The segment is expected to grow in the tetanus toxoid vaccine market owing to factors such as increased government initiatives to control diphtheria, tetanus, and pertussis, a rise in product launches, and an increase in pipeline studies for the development of DTaP vaccines.
  
• This vaccination coverage helps safeguard infants against infectious diseases that have the potential to cause severe illness, disability, or even mortality.
  
• Thus, an increase in diphtheria-tetanus-pertussis cases is likely to demand the availability of vaccines and thereby driving the segment growth.

Learn more about the key segments shaping this market

Download Free PDF

The tetanus toxoid vaccine market by age group is categorized into pediatric and adult. The paediatric segment dominated around USD 3.7 billion revenue in 2023.

• The development and introduction of tetanus toxoid-containing vaccines specifically designed for newborns contribute to the growth of the segment. These vaccines are formulated to provide early protection against tetanus in the first days or weeks of life, complementing maternal immunization efforts and ensuring comprehensive protection for newborns.
  
• Additionally, the advancements in vaccine technology and manufacturing capabilities have facilitated the development of safer and more effective tetanus toxoid vaccines for children, thus augmenting the market growth.

Based on end-use, the tetanus toxoid vaccine market is segmented into hospitals and clinics, government organizations, and other end-users. The hospitals and clinics segment accounted for 52.2% of the market share in 2023.

• Hospitals play a vital role in delivering complete healthcare services, including vaccination programs, thereby accelerating segmental growth.
  
• Furthermore, hospitals frequently have access to a diverse patient population, including those at higher risk of infectious diseases. This will give an opportunity to improve the acceptance of vaccines and encourage preventive healthcare practices within the hospital community, therefore foster future market growth.

Looking for region specific data?

Download Free PDF

North America tetanus toxoid vaccine market size held over USD 2 billion in 2023.

• North America is predicted to dominate the tetanus toxoid vaccine industry owing to factors such as a favorable regulatory environment coupled with the growing prevalence of tetanus and diphtheria, which is expected to augment regional growth.
  
• Additionally, collaborations between research institutions, pharmaceutical companies, and government organizations in the region will lead to advancements in vaccine research and development. These collaborations are expected to promote innovation, therefore accelerating the development of new toxoid vaccines, and contributing to the market growth.
  

Tetanus Toxoid Vaccine Market Share

The tetanus toxoid vaccine industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc among others have a notable presence in the market.

Tetanus Toxoid Vaccine Market Companies

Some of the eminent market participants operating in the tetanus toxoid vaccine industry include:

• Bharat Biotech International Limited
• Biological E. Limited
• Biological Products Institute (BPI) Argentina
• Chengdu Institute of Biological Products Co., Ltd.
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Panacea Biotec
• Pfizer Inc.
• Sanofi
• Serum Institute of India
• Zydus Group
  

Tetanus Toxoid Vaccine Industry News

• In December 2023, Panacea Biotec Limited launched the world's first fully-liquid wP-IPV-based pentavalent vaccine, EasyFourPol, in India. This innovative vaccine provides protection against five life-threatening diseases, including Tetanus, Diphtheria, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type B. This launch led to a significant milestone for the company in the field of vaccination and is anticipated to have a positive impact on child healthcare.
  
• In October 2022, GlaxoSmithKline announced the U.S. Food and Drug Administration (FDA) approval for BOOSTRIX (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed; Tdap) for immunization during the third trimester of pregnancy to help prevent pertussis in infants younger than two months of age. This is the first vaccine indicated in the U.S. to help protect infants younger than two months. This strategic initiative helped the company to offer a competitive edge in the market.
  

The tetanus toxoid vaccine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Tetanus toxoid (TT)
• Diphtheria and tetanus (DT)
• Tetanus and diphtheria (Td)
• Diphtheria, tetanus, and pertussis (DTaP)
• Tetanus, diphtheria, and pertussis (Tdap)
• Diphtheria, tetanus, pertussis, Hib and hepatitis B (DTP-Hib-HepB)
• Pentavalent (DTaP-IPV/Hib)
• Hexavalent (DTaP-IPV/Hib-HepB)
• Other vaccine types

Market, By Age Group

• Pediatric
• Adult

Market, By End-use

• Hospitals and clinics
• Government organizations
• Other end-users

The above information has been provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa